Drugs / Bone Morphogenetic Protein 2
Bone Morphogenetic Protein 2
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01725698 | Nov 2012 → Dec 2014 | — | Indonesia University | Unknown | No outcome recorded |
| Phase 1 | NCT01690260 | Sep 2004 → Oct 2017 | disease of bone structure, osteoarthritis | Northern Orthopaedic Division, Denmark | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04368650 | Dec 2017 → Sep 2019 | periodontitis | SVS Institute of Dental Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01958502 | Jul 2013 → Jul 2014 | — | Emdadi Kamyab Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2016-03-21 | Ethris GmbH | Results Ethris publishes Preclinical Data on Musculoskeletal Regeneration using its novel mRNA-based Transcript Therapy Approach ethris.com ↗
The paper demonstrates that a modified mRNA construct based on Ethris’ technology coding for the human growth factor BMP-2 (bone morphogenetic protein-2) can induce bone regeneration in three different settings including an established in vivo model for bone healing. |
| 2010-10-01 | Daewoong Pharmaceutical Co. LTD. | Regulatory Daewoong received the clinical permission for ‘NOVOSIS’, an innovative medical device daewoong.co.kr ↗
Daewoong Pharmaceutical Co., Ltd. (CEO Lee, Jong Wook) obtains an authorization for ‘NOVOSIS’, a complex between bone graft materials and BMP-2(a protein of osteoplastic promotion) as new medical device. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2016-03-21 | Ethris GmbH | Ethris publishes Preclinical Data on Musculoskeletal Regeneration using its novel mRNA-based Transcript Therapy Approach ethris.com ↗ |
| 2010-10-01 | Daewoong Pharmaceutical Co. LTD. | Daewoong received the clinical permission for ‘NOVOSIS’, an innovative medical device daewoong.co.kr ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bone morphogenetic protein-2 | “combination of bone marrow-derived mesenchymal stem cells (BM-MSCs), hydroxyapatite (HA) granules, bone morphogenetic protein-2 (BMP-2), and internal fixation for treating CSDs.” PMID 30747273 ↗ Feb 2019 |
| Known as | BMP-2 | “12 mg recombinant BMP-2 combined with an injection of 1-2 g collagen type 1.” NCT01690260 ↗ |
| Known as | Bone morphogenetic protein 2a | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068575 ↗ |
| Known as | Human Bone Morphogenetic Protein-2 | “lyophilized Human Bone Morphogenetic Protein-2 was used as an active drug.” NCT04368650 ↗ |
| Modality | Protein / enzyme biologic | “recombinant growth factor BMP-2” NCT01690260 ↗ |
| Route | Other | “implant in collagenic 3-D scaffold with BMP-2 and put in non union site by surgical approach under general or spinal anesthesia as deemed appropriate by the anesthetist.” NCT01958502 ↗ |